Mineralys Therapeutics, Inc. (MLYS) Earnings
Mineralys Therapeutics, Inc. is expected to report next earnings on August 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.54. MLYS has beaten EPS estimates in 6 of its last 8 reported quarters (average surprise +11.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-0.51 | $-0.47 | +7.8% | — | — |
| Mar 12, 2026 | $-0.52 | $-0.40 | +22.5% | — | — |
| Aug 12, 2025 | $-0.78 | $-0.66 | +15.4% | — | — |
| Feb 12, 2025 | $-1.00 | $-0.98 | +2.0% | — | — |
| May 9, 2024 | $-0.68 | $-0.70 | -2.9% | — | — |
| Mar 21, 2024 | $-0.85 | $-0.61 | +28.2% | — | — |
| May 15, 2023 | $-0.71 | $-0.51 | +28.2% | — | — |
| Mar 15, 2023 | $1.72 | $-1.74 | -201.2% | — | — |
| Jun 30, 2022 | — | $-0.35 | — | — | — |
| Mar 31, 2022 | — | $-0.41 | — | — | — |
| Dec 31, 2021 | — | $-0.18 | — | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
John Congleton began by overviewing the business, clinical programs, and recent milestones. The FDA accepted the NDA for lorunderstat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs and assigned a PDUFA target date of December 22, 2026. Operational focus is on preparing lorunderstat for a successful launch in the US, evaluating partnering opportunities, and considering next steps in clinical development. Adam Levy then reviewed first quarter financial results, noting cash, R&D, G&A expenses, other income net, and net loss figures.
Guidance
The company believes current cash, cash equivalents, and investments will be sufficient to fund planned clinical trials and regulatory activities, as well as support corporate operations into 2028. They continue to evaluate partnering opportunities and are focused on preparing lorunderstat for a strong commercial launch.
Segment performance
Cash, cash equivalents, and investments ended the quarter at $646.1 million as of March 31, 2026, down from $656.6 million as of December 31, 2025. R&D expenses for the quarter ended March 31, 2026 were $24.4 million, down from $37.9 million in the same quarter of 2025. G&A expenses were $21 million for the quarter ended March 31, 2026, up from $6.6 million in the same quarter of 2025. Total other income net was $6 million for the quarter ended March 31, 2026, up from $2.2 million in the same quarter of 2025. Net loss was $39.3 million for the quarter ended March 31, 2026, down from $42.2 million in the same quarter of 2025.